Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Crispr Therapeutics Ag (CRSP)

Crispr Therapeutics Ag (CRSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,154,984
  • Shares Outstanding, K 85,353
  • Annual Sales, $ 371,210 K
  • Annual Income, $ -153,610 K
  • EBIT $ -332 M
  • EBITDA $ -313 M
  • 60-Month Beta 1.62
  • Price/Sales 11.46
  • Price/Cash Flow N/A
  • Price/Book 2.19

Options Overview Details

View History
  • Implied Volatility 51.38% ( +0.03%)
  • Historical Volatility 63.60%
  • IV Percentile 16%
  • IV Rank 15.65%
  • IV High 82.92% on 02/15/24
  • IV Low 45.53% on 08/26/24
  • Put/Call Vol Ratio 0.54
  • Today's Volume 3,694
  • Volume Avg (30-Day) 7,723
  • Put/Call OI Ratio 0.61
  • Today's Open Interest 85,509
  • Open Int (30-Day) 80,337

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.21
  • Number of Estimates 12
  • High Estimate -0.74
  • Low Estimate -1.93
  • Prior Year 1.10
  • Growth Rate Est. (year over year) -210.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
45.51 +5.61%
on 11/21/24
55.50 -13.40%
on 12/02/24
-6.80 (-12.39%)
since 11/11/24
3-Month
44.43 +8.18%
on 09/12/24
59.07 -18.63%
on 11/11/24
+2.63 (+5.78%)
since 09/11/24
52-Week
43.42 +10.70%
on 09/06/24
91.10 -47.24%
on 02/22/24
-12.22 (-20.26%)
since 12/11/23

Most Recent Stories

More News
CRISPR Therapeutics Announces RMAT Designation for CTX112™ Following Promising Phase 1 Data in CD19-Positive B-cell Malignancies

Preliminary data show CTX112™ may benefit patients with certain B-cell malignancies; RMAT designation granted by FDA.Quiver AI SummaryCRISPR Therapeutics announced that preliminary data from its Phase...

CRSP : 47.72 (-1.97%)
2 Biotech Stocks to Buy Hand Over Fist in December

The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark, is up 9% this year compared to 28% for the S&P 500 . Will that trend continue in 2025?...

CRSP : 47.72 (-1.97%)
EXEL : 35.16 (-0.20%)
3 of the Best Growth Stocks You Can Buy for Less than $100

It's getting harder these days to find great growth stocks trading for less than $100 a share. It almost seems like a higher price is one of the criteria. But investors should know that there are plenty...

KBH : 74.62 (-3.34%)
CELH : 30.21 (-1.31%)
CRSP : 47.72 (-1.97%)
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More than 65%

Ark Invest chief Cathie Wood is known for scooping up shares of innovators early in their growth stories and holding on for the long term. The idea is to get in on these players for a bargain price, and...

CRSP : 47.72 (-1.97%)
Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip?

On Nov. 21, shares of CRISPR Therapeutics (NASDAQ: CRSP) were down 47% from a peak they reached in March. This might be a little surprising to folks who have been following this developer of gene therapies....

CRSP : 47.72 (-1.97%)
VRTX : 465.57 (-0.78%)
3 Monster Stocks in the Making

Godzilla and King Kong surely weren't born big. They began small and grew over time to their gargantuan sizes even if the movies don't tell their childhood stories.

VKTX : 48.61 (+1.59%)
CRSP : 47.72 (-1.97%)
SMMT : 18.84 (+4.84%)
Deciphering Disruption: Inside Cathie Wood's Latest Plays

Cathie Wood's recent stock market activity offers a glimpse into her evolving investment strategy and the potential of disruptive technologies.

GH : 36.10 (+1.60%)
CRSP : 47.72 (-1.97%)
TSLA : 416.63 (+3.90%)
PACB : 2.31 (-1.28%)
TTD : 134.69 (+1.53%)
U : 27.15 (+2.84%)
MRNA : 42.04 (+1.28%)
AMZN : 230.08 (+2.24%)
COIN : 316.77 (+4.75%)
SQ : 98.11 (+4.33%)
PLTR : 72.26 (+1.93%)
ARKK : 61.74 (+1.90%)
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More

Biotechs often need several years to realize their visions, even after they have a drug approved for the first time. There's typically plenty of upside in store for enterprising and patient investors.

CRSP : 47.72 (-1.97%)
IOVA : 8.44 (-1.75%)
VRTX : 465.57 (-0.78%)
Where Will CRISPR Therapeutics Be in 3 Years?

CRISPR Therapeutics (NASDAQ: CRSP) made a name for itself by pioneering advanced gene therapies made with technologies that didn't exist a generation ago. Now, its challenge is to build on its prior successes...

CRSP : 47.72 (-1.97%)
3 Unstoppable Growth Stocks I'm Loading $25,000 Each Into by 2029

These three emerging technology leaders are pioneering quantum computing, gene editing, and electric aviation.

NVDA : 139.66 (+3.40%)
ACHR : 7.24 (-6.22%)
CRSP : 47.72 (-1.97%)
IONQ : 31.49 (-4.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is rapidly leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases.

See More

Key Turning Points

3rd Resistance Point 52.19
2nd Resistance Point 51.35
1st Resistance Point 50.01
Last Price 47.72
1st Support Level 47.83
2nd Support Level 46.99
3rd Support Level 45.65

See More

52-Week High 91.10
Fibonacci 61.8% 72.89
Fibonacci 50% 67.26
Fibonacci 38.2% 61.63
Last Price 47.72
52-Week Low 43.42

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar